Navigation Links
MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
Date:8/19/2007

s listed in the table below.

Teplizumab Clinical Trials

Study Brief Description Additional Information

Protege trial Global Phase 2/3 trial http://www.protegediabetes.com

for patients with http://www.clinicaltrials.gov

recent-onset type 1 (search for Protege)

diabetes mellitus (less

than or equal to 12

weeks from symptoms)

ages 8-35 with treatment

at the start of the

study and again at

six months

AbATE trial Led by Dr. Kevan Herold http://www.abatetrial.org

of Yale University, http://www.clinicaltrials.gov

this Phase 2 trial, (search for NCT00129259)

funded by the Immune

Tolerance Network and

NIAID, will evaluate

patients with recent-

onset type 1 diabetes

mellitus (less than

or equal to 6 weeks

from diagnosis) ages

8-30 with treatment at

the start of the study

and again at one year

Delay Study Led by Dr. Kevan Herold http://www.clinicaltrials.gov

of Yale University, (search for NCT00378508)

this Phase 2 trial funded

by NIDDK is for patients

ages 8-30 with type 1


'/>"/>

SOURCE MacroGenics, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace
4. Global Rabies Treatment May be Possible with NanoViricides Drugs
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014  Decision Resources Group finds that the market ... $7.7 billion by 2023 in the United States ... , Italy , Spain ... Japan . The biosimilar erosion of Roche/Genentech/Chugai,s ... out by the launch of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s ...
(Date:8/28/2014)... CHARLOTTE, N.C. , Aug. 28, 2014 /PRNewswire/ ... innovation marketplace, today announced a worldwide search for ... of the senior population.  Promising ideas uncovered through ... presented to leading medical device manufacturers and healthcare ... to improve the lives of individuals age 65 ...
(Date:8/28/2014)... 2014 /PRNewswire-iReach/ -- Gateway Analytical announced today that ... Annual Global Pharma Manufacturing Summit in ... . The Global Pharma Manufacturing Summit offers a ... and biologic pharmaceutical manufacturing. The conference is focused ... face, such as the increasing pressure to grow ...
Breaking Medicine Technology:The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 3Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3
... JUNCTION, N.J., Feb. 28, 2012  Insmed Incorporated (Nasdaq CM: INSM), ... Tuesday, March 13th, 2012, at 8:30 AM ET, to ... year-end 2011.  Insmed intends to issue its quarterly and ... on March 13th. To participate in ...
... LONDON, Feb. 28, 2012  Based on its recent ... Sullivan recognises Brainsway with the 2012 Global Frost ... deep Transcranial Magnetic Stimulation (dTMS) is the only ... treatment of depression and other neuro-psychiatric disorders without ...
Cached Medicine Technology:Insmed to Host Fourth Quarter and 2011 Year-End Earnings Conference Call 2Insmed to Host Fourth Quarter and 2011 Year-End Earnings Conference Call 3Frost & Sullivan New Product Innovation Award Presented to Brainsway for Its Deep Transcranial Magnetic Stimulation (dTMS) Device 2Frost & Sullivan New Product Innovation Award Presented to Brainsway for Its Deep Transcranial Magnetic Stimulation (dTMS) Device 3
(Date:8/29/2014)... these recent findings, there has been a significant rise in ... few years. Medical expert and Herpes researcher, Dr. Williams said, ... that make it hard for patients to find out if ... the exact symptoms of these ailments, others confuse it with ... of cases over the years has been a cause of ...
(Date:8/29/2014)... 2014 Hope For The Warriors® is ... Scholarships. Scholarships are awarded two times each year to ... spouses of fallen service members. Hope For The Warriors® ... of self, restoring the family unit, and restoring hope ... , The Spouse/Caregiver Scholarship Program identifies, recognizes, and rewards ...
(Date:8/29/2014)... First Choice Emergency Room opened its new ... facility is located 1501 FM 685, Pflugerville, Texas and is ... a part of First Choice Emergency Room’s second location in ... quality emergency medical care to the local community,” said Dr. ... Pflugerville – FM 685. , To celebrate the ...
(Date:8/29/2014)... North York, ON (PRWEB) August 29, 2014 ... busy professional needs to find a break in their day ... not always easy for business professionals to find a few ... this announcement by North York Dental so important. It is ... emergency care that they need. , What is happening? , ...
(Date:8/29/2014)... 2014 http://www.fdanews.com/CTMPR , FDAnews ... Magnifier Weekly. , Clinical Trial Magnifier Weekly monitors 150,000 ... and reports all the fresh changes. By sifting through ... extract just the information readers need. Subscribers are able ... links in the newsletter to focus on the ones ...
Breaking Medicine News(10 mins):Health News:It was reported that the Number on PositiveSingles.dating increased about 20% in 2014 2Health News:Hope For The Warriors Announces Fall 2014 Spouse/Caregiver Scholarship Recipients 2Health News:Hope For The Warriors Announces Fall 2014 Spouse/Caregiver Scholarship Recipients 3Health News:First Choice Emergency Room Opens New Facility in Pflugerville, Texas 2Health News:North York Dental Provides Dental Services to Busy Professionals 2Health News:FDAnews Accounces New Newsletter: Clinical Trial Magnifier Weekly Provides the Most Up-to-Date Clinical Trial Data 2Health News:FDAnews Accounces New Newsletter: Clinical Trial Magnifier Weekly Provides the Most Up-to-Date Clinical Trial Data 3Health News:FDAnews Accounces New Newsletter: Clinical Trial Magnifier Weekly Provides the Most Up-to-Date Clinical Trial Data 4
... Vitamin supplements can prevent hearing loss in laboratory ... step closer to the development of a pill that ... loss in humans. , The findings will be reported ... conference in Baltimore by senior author Colleen Le Prell, ...
... has experts available to discuss the current debate on ... January, Baker Institute fellows Neal Lane and Kirstin Matthews ... Obama administration. They recommend that stem cell research be ... manner and that a federal stem cell policy be ...
... 17 The National Head Start Association ... Chairperson Ron Herndon, who also is the director of ... thousands of new jobs will be created -- and ... now that President Barack Obama has signed into law ...
... GCC is the strongest independent, ... predictor of colorectal cancer recurrence -, ... 17 /PRNewswire-FirstCall/ - The Journal of the American Medical Association ... a major prospective 5-year multicenter study of over 400 enrolled ...
... Company Posts Quarterly EPS of $0.39, Total Revenues of ... by 23%, Total Revenues by 17% -- Company Generates ... Feb. 17 Gen-Probe Incorporated (Nasdaq: ... the fourth quarter and full year ended December 31, ...
... INCREASE 23 PERCENTSAN DIEGO, Feb. 17 Volcano Corporation ... development, manufacturing and sales of products for the diagnosis ... reported that revenues for the full year 2008 increased ... for the fourth quarter of 2008 increased 23 percent ...
Cached Medicine News:Health News:Vitamin supplements may protect against noise-induced hearing loss 2Health News:Vitamin supplements may protect against noise-induced hearing loss 3Health News:NHSA: President Obama, Congress Deserve High Praise for $2.1 Billion in Recovery Package for Head Start 2Health News:Major study on DiagnoCure's GCC biomarker published in Jama 2Health News:Major study on DiagnoCure's GCC biomarker published in Jama 3Health News:Major study on DiagnoCure's GCC biomarker published in Jama 4Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 2Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 3Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 4Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 5Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 6Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 7Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 8Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 9Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 10Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 11Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 12Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 13Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 14Health News:Volcano Reports Full Year Revenues Increase 31 Percent 2Health News:Volcano Reports Full Year Revenues Increase 31 Percent 3Health News:Volcano Reports Full Year Revenues Increase 31 Percent 4Health News:Volcano Reports Full Year Revenues Increase 31 Percent 5Health News:Volcano Reports Full Year Revenues Increase 31 Percent 6Health News:Volcano Reports Full Year Revenues Increase 31 Percent 7Health News:Volcano Reports Full Year Revenues Increase 31 Percent 8Health News:Volcano Reports Full Year Revenues Increase 31 Percent 9Health News:Volcano Reports Full Year Revenues Increase 31 Percent 10Health News:Volcano Reports Full Year Revenues Increase 31 Percent 11Health News:Volcano Reports Full Year Revenues Increase 31 Percent 12Health News:Volcano Reports Full Year Revenues Increase 31 Percent 13Health News:Volcano Reports Full Year Revenues Increase 31 Percent 14
... offers a truly unique surgical approach for ... (IOFB). Other magnets are available for ophthalmic ... electromagnet for use through a pars plana, ... D.O.R.C. Intraocular Electromagnet offers the most effective ...
... Earth Intraocular Magnet is especially designed for ... bodies. The precise, sleek design of this ... with electromagnetic devises. Due to its 24K ... possibility of secondary foreign body incarceration. The ...
... SureSigns C1 compact, portable monitor features ... as well as versatile spot check ... ideal for transport and low-acuity care, ... and provides the flexibility required for ...
... the M3 and M4 monitors offer wireless ... care. M Series monitors are equipped with ... set of non-invasive parameters and input for ... extensions offer Mainstream or Microstream® CO 2 ...
Medicine Products: